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Abstract
Introduction: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a marker of vascular inflammation associated with coronary heart disease and 
stroke. We evaluated analytical performance of the PLAC® Activity Test on Siemens Dimension Vista® 1500 analyzer and measured Lp-PLA2 activity 
in Italian adults to establish reference intervals (RIs) and evaluate correlation with circulating lipids and age.
Materials and methods: The evaluation protocol consisted of precision, linearity, sensitivity, method comparison, substrate depletion (“hook”) 
effect and interference assessment. Inhibitor (Darapladib) effect was also evaluated. Lp-PLA2 activity was measured in 250 healthy donors (123 ma-
les, 127 females, aged 18-70 years). Central 95% RIs were established using nonparametric statistics.
Results: Intra-assay and inter-assay precision showed CVs of 0.6% - 1.4% and 0.9% - 2.0%, respectively. Linearity replicates showed R2 > 0.98. 
Limit of quantitation was 5.8 U/L (CV = 9.4%). Bland Altman plot showed bias - 0.9, 95% limits of agreement -6.5 - 4.72. Passing-Bablok regression 
showed excellent correlation (Slope = 1.02, 95% CI: 1.01 to 1.03; Intercept = - 1.86, 95% CI: - 3.08 to - 1.26; R2 = 0.999). No “hook effect” was ob-
served at Lp-PLA2 activities ≤ 1000 U/L. Average Lp-PLA2 activity in 250 healthy donors was 182 ± 44 U/L (mean ± SD). Males showed statistically 
significant higher activities than females (P < 0.001). RIs were 107 - 265 U/L for males and 84 - 225 U/L for females. Moderate significant correlation 
(r = 0.29, P < 0.001) was found between Lp-PLA2 activity and total cholesterol.
Conclusions: The PLAC® Activity Test shows very good performance characteristics on Dimension Vista® 1500.
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Lipoprotein-associated phospholipase A2 (Lp-
PLA2), also known as platelet-activating factor 
acetyl-hydrolase, is a calcium-independent serine 
lipase which was initially identified by its hydrolys-
ing action on the acetyl group at the sn-2 position 
of platelet-activating factor (1). It is now known 
that Lp-PLA2 can hydrolyse a broad spectrum of 
substrates, including oxidized and polar phos-
phatidylcholines (2). Lp-PLA2 is synthesized by 
macrophages and other inflammatory cells and 
circulates in human blood mainly bound to low-
density lipoprotein (LDL) particles (80 - 85%) and, 
to a lesser extent, to high-density lipoprotein 
(HDL) (3). Although it is considered an atheropro-
tective enzyme, the hydrolysis of oxidized phos-
pholipids generates lysophospholipids, com-
pounds that have a pro-inflammatory function (4). 
Several lines of evidence indicate that oxidized 
LDL play a critical role in atherogenesis and Lp-
PLA2 has been shown to be involved in the oxida-
tive modification of LDL in the vascular wall by hy-
drolysing oxidized phospholipids, generating 
lysophosphatidylcholine and oxidized non-esteri-
fied fatty acids, which are strong pro-inflammato-
ry mediators contributing to the formation of the 
atherosclerotic plaque (4-6). Lp-PLA2 is a highly 
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specific marker of vascular inflammation and its 
role in the development and progression of ather-
osclerosis has been suggested by various authors 
(6-8). High Lp-PLA2 activity during atherosclerotic 
plaque formation and other inflammatory pro-
cesses have been shown in several studies and 
there is increasing evidence that this enzyme is 
present within atherosclerotic lesions and en-
riched in vulnerable regions (6,8-11). Along with 
the well-known inflammatory marker high sensi-
tivity C-reactive protein, Lp-PLA2 has gained in-
creasing significance and has been identified as an 
independent predictor of cardiovascular disease 
(CVD) in several studies, with elevated Lp-PLA2 ac-
tivities associated with an increased risk of CVD 
(7,8,12,13). Moreover, since half of first cardiovascu-
lar events occur in apparently healthy subjects 
showing normal lipid profiles, Lp-PLA2 measure-
ment can be of particular clinical relevance in pri-
mary prevention, as it could help identify patients 
with unrecognized cardiovascular risk when the 
evaluation of traditional risk markers is not suffi-
ciently informative (8,14,15). A consensus panel is-
sued in 2008 recommended testing Lp-PLA2 not 
only as a diagnostic test for vascular inflammation 
but also in adjunct to traditional risk factor assess-
ment in individuals with moderate or high risk of 
cardiovascular disease as defined by Framingham 
risk scores (16). This would allow improved identifi-
cation of patients at high or very high CVD risk 
who would benefit from intensification of lipid-
modifying therapy, and a lower LDL-cholesterol 
goal concentration is suggested when Lp-PLA2 ac-
tivities are high (17). Different assays for the meas-
urement of Lp-PLA2 activity in human plasma and 
serum have been developed but to date only the 
PLAC® Test for Lp-PLA2 Activity Kit (diaDexus, Inc., 
San Francisco, USA) has received clearance by the 
Food and Drug Administration (FDA), in December 
of 2014.
In the present study we evaluated the analytical 
characteristics of the PLAC® Test on a Siemens Di-
mension Vista® 1500 analyzer (Siemens Healthcare 
Diagnostics Inc., Newark, USA), which is currently 
installed in our Core Clinical Chemistry Laboratory 
in an automated configuration. Since reference in-
tervals (RIs) for Lp-PLA2 activity in the Italian popu-
lation have not been reported yet, we analysed se-
rum samples from a cohort of Italian healthy vol-
unteers and evaluated the distribution of Lp-PLA2 
activity and the correlation of serum Lp-PLA2 ac-
tivity with circulating lipids and age.
Materials and methods
Subjects
For the reference population, serum samples were 
retrospectively selected from stored spare sam-
ples obtained from healthy volunteers, which 
were previously recruited at Tor Vergata University 
Hospital. We selected spare serum samples from 
250 apparently healthy volunteers (123 males, 127 
females), median age 37 (18 - 70) years. All subjects 
had undergone a visit consisting of a medical his-
tory, a physical examination, blood pressure meas-
urement, and routine laboratory blood tests (clini-
cal chemistry, haematology, coagulation), and had 
given informed consent for the collection, storage 
and/or reuse of blood samples. Exclusion criteria 
for our study were history and/or signs of CVD, any 
chronic disease or severe medical condition, alco-
hol and/or drug abuse, hypertension (systolic 
blood pressure ≥ 140 mm Hg and/or diastolic 
blood pressure ≥ 90 mmHg or under antihyper-
tensive medication), total cholesterol > 5.2 
mmol/L, triglycerides > 1.8 mmol/L, and use of li-
pid-lowering agents. Fasting blood samples had 
been collected into BD Vacutainer® SST™ II Ad-
vance Plus serum separator tubes (Becton, Dickin-
son and Company, Franklin Lanes, USA) following 
standard procedures. Sample storage conditions 
were derived from previously published stability 
studies (18,19). Briefly, samples were selected on a 
daily basis after completion of routine laboratory 
assessments, which were performed within 1 - 2 
hours of collection. Selected blood samples were 
anonymized and either stored at 4 °C and ana-
lysed for Lp-PLA2 activity within 1 week or aliquot-
ed and stored at - 70 °C for a maximum of 3 
months and then analysed after a single freeze-
thaw cycle. 
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Methods
Lp-PLA2 enzyme activity
Lp-PLA2 activity was determined on an open, us-
er-defined channel on the Siemens Dimension Vis-
ta® 1500 automated chemical analyser (Siemens 
Healthcare Diagnostics Inc., Newark, DE, USA) us-
ing the PLAC® Test Activity Kit developed by dia-
Dexus (diaDexus, Inc., San Francisco, CA) for the 
quantitative determination of Lp-PLA2 activity in 
human plasma and serum. Principle of the test is 
based on Lp-PLA2 hydrolysing the sn-2 position of 
the substrate, 1-myristoyl-2-(4-nitrophenylsucci-
nyl) phosphatidylcholine, and producing a col-
oured reaction product, 4-nitrophenol. Lp-PLA2 
activity was determined by spectrophotometrical-
ly monitoring the rate of 4-nitrophenol formation 
at 405 nm (secondary wavelength 510 nm) for 10 
minutes, according to previously published meth-
ods (20,21). A minimum serum sample volume of 
200 μL was required. Total reagent volume to fill 
an empty Siemens Flex® (Siemens Healthcare Di-
agnostics Inc., Newark, USA) cartridge was 12.0 mL 
for R1 (buffer) and 3.2 mL for R2 (substrate). Work-
ing volumes for a single test were 100 μL for R1 
and 25 μL for R2. Under these conditions, 104 tests 
could be run with each cartridge. A 5-point cali-
bration was performed using a set of five calibra-
tors made with purified recombinant Lp-PLA2 pro-
tein to generate activities of 0, 50, 100, 250, and 
400 U/L, respectively. Calibrators were measured 
in triplicate. Calibration was verified by measuring 
high and low activity controls provided with the 
kit. Lp-PLA2 activity was derived from the calibra-
tion curve by plotting change in absorbance ver-
sus Lp-PLA2 activity in U/L. 
Serum samples for method validation were pro-
vided by diaDexus. These samples had been previ-
ously obtained from healthy volunteers and stored 
at − 70 °C. For the present study, samples were 
shipped on dry ice and were received frozen.
Precision
Assay precision was evaluated according to the 
EP15-A2 document of the Clinical and Laboratory 
Standards Institute (CLSI), using 5 different sam-
ples (2 controls and 3 serum samples) with known 
Lp-PLA2 activity distributed throughout the cali-
bration range of the assay (22). Intra-assay preci-
sion was evaluated by running 20 replicates of 
each sample in a single assay run. Inter-assay pre-
cision was evaluated by running 4 replicates of 
each sample on 5 different days, with a new cali-
bration every day.
Sensitivity
Assay sensitivity was evaluated by analysing 4 
samples with known low Lp-PLA2 activity (range 0 
- 10 U/L) in 5 replicates over 5 calibration runs on 5 
different days, for a total of 25 replicates for each 
sample. As specified by the manufacturer, prede-
fined goals for bias and imprecision were respec-
tively ± 5% difference from reference value and a 
coefficient of variation (CV) < 20% at the limit of 
quantitation (LoQ).
Linearity 
Assay linearity was determined by serial recovery 
studies performed on 3 pairs of different serum sam-
ples with high or low Lp-PLA2 activity (range: 96 – 
328 U/L). In each serum pair, samples were mixed at 
ratios of 0:100, 10:90, 20:80, 30:70, 40:60, 50:50, 60:40, 
70:30, 80:20, 90:10, and 100:0, for a total of 11 activity 
levels which were measured in duplicate and then 
compared to expected calculated results.
Method comparison
Since there is no gold standard for Lp-PLA2 activi-
ty to assess assay accuracy, the Bland-Altman plot 
was used to perform method comparison be-
tween the Dimension Vista® 1500 and the analyti-
cal platform used by the manufacturer. Lp-PLA2 
activity was measured in duplicates in a single as-
say run on 40 blind serum samples spanning an 
activity range of 5 - 365 U/L, which were provided 
by diaDexus. Our results were then compared to 
the activity values previously measured by dia-
Dexus on the same samples using a Beckman 
Coulter AU400® analyser (Beckman Coulter Inc., 
Brea, USA).  
Hook effect
The effect of substrate depletion due to high con-
centrations of Lp-PLA2 protein on the measure-
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ment of its enzymatic activity (“hook effect”) was 
evaluated as follows: purified recombinant Lp-
PLA2 was diluted into the calibrator matrix to nom-
inal Lp-PLA2 activities of 0, 50, 75, 150, 225, 300, 
400, 600, 750, 1000, 1250, 1500, and 2000 U/L. 
These samples were then analysed in duplicate. 
The concentration of recombinant Lp-PLA2 was 
measured by the Bradford protein assay.
Analytical interferences
For interference testing, selected serum samples 
with Lp-PLA2 activity in the range of 96 to 239 U/L 
were spiked with different levels of potentially in-
terfering endogenous substances. A 6841.5 
μmol/L bilirubin stock solution (Sigma-Aldrich Inc, 
St. Louis, MO, USA) was diluted in 0.1 M NaOH and 
spiked in serum samples to a concentration of 
342.1 μmol/L. A 200 g/L albumin stock solution 
(Calbiochem, San Diego, CA, USA) was diluted in 
distilled water and spiked in serum samples to a 
concentration of 50 g/L. Baseline albumin concen-
tration was also measured in each sample and to-
tal albumin (baseline + supplementary) was taken 
into account for interference evaluation. 
Haemolysate solution (in-house, 105 g/L haemo-
globin) and Intralipid® 20% emulsion (Sigma-Al-
drich Inc, St. Louis, USA; 20% = 2.3 mmol/L triglyc-
erides) were ready to use. Serum samples with re-
spectively 1.5 g/L, 1.25 g/L, and 1.0 g/L 
haemolysate were prepared. Intralipid® emulsion 
to a final triglycerides concentration of 2.8 mmol/L 
was added to selected serum samples. For each 
substance, controls were prepared by spiking se-
rum samples with the corresponding solvent, 
when appropriate. Bilirubin, albumin and Intralip-
id® (triglycerides) were measured on the Dimen-
sion Vista® 1500 instrument. Haemoglobin 
(haemolysate) stock solution was measured on the 
XE-2100 automated haematology analyser (Sys-
mex, Kobe, Japan).
Lp-PLA2 enzyme inhibition
A 5 mM stock solution of the Lp-PLA2 inhibitor 
Darapladib was serially diluted in dimethyl sulfox-
ide (DMSO) in order to obtain 11 dilution levels 
with inhibitor concentrations ranging from 0.50 
nM to 500 nM. Four different serum samples (Lp-
PLA2 activity range: 97 - 243 U/L) were divided into 
232 μL aliquots and 8 μL of each Darapladib dilu-
tion were spiked into individual aliquots from all 4 
sera, for a total of 44 test samples. Lp-PLA2 activity 
was measured in inhibitor spiked aliquots, un-
spiked aliquots, and aliquots spiked with 8 μL of 
DMSO alone as a control. Measured values were 
used to fit a dose-response curve for the determi-
nation of the in vitro half-maximal inhibitory con-
centration (IC50) of Darapladib.
On-board reagent stability
The R1 (buffer) and R2 (substrate) reagents were 
transferred to the specific Flex® cartridge and 
stored at 2 - 8 °C in the refrigerated compartment 
of the Dimension Vista® 1500 instrument for a max-
imum of 4 weeks. Lp-PLA2 activity was measured 
in triplicate on high and low controls 3 times a 
week over a window of 28 days, for a total of 72 
determinations, always using the same reagent set 
and calibration curve performed at day 0. Lp-PLA2 
activity variations of ± 5% from initial value were 
considered acceptable.
Statistical analysis
Statistical analysis was performed using MedCalc 
for Windows, version 13.0 (MedCalc Software, Os-
tend, Belgium). Method comparison between the 
Dimension Vista® 1500 and the Beckman AU400® 
was performed by Bland-Altman plot and Passing-
Bablok regression analysis. The Kolmogorov-
Smirnov test was used to assess the normality of 
distribution of Lp-PLA2 activity in the whole study 
population, and in males and females separately. 
Reference intervals were defined according to CLSI 
document C28-A3 using the nonparametric meth-
od (minimum sample size required for each parti-
tion group: N = 120) and central 95th percentile of 
reference values (23). Differences between genders 
were tested by unpaired t-test. Spearman’s and 
Pearson’s correlation test was used to test the asso-
ciation between serum Lp-PLA2 activity and serum 
concentrations of total cholesterol, LDL-cholesterol 
(directly measured), HDL-cholesterol, and triglycer-
ides and the association between serum Lp-PLA2 
activity and age in the study population. The values 
P < 0.05 were considered statistically significant.
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Results
Intra-assay variability analysis yielded within–run 
CVs ranging from 0.6% to 1.4% (Table 1). Inter-as-
say variability analysis yielded between-run CVs 
ranging from 0.9% to 2.0% (Table 1).
LoQ was determined as 5.8 U/L with a CV of 9.4%. 
Linear regression analysis of Lp-PLA2 activity val-
ues (range: 96 - 328 U/L) from the serial recovery 
assay samples compared to expected activity val-
ues resulted in slopes ranging from 1.009 to 1.013, 
intercepts ranging from - 1.134 to 3.097 and R2 
ranging from 0.998 to 0.999. Detailed results are 
reported in Table 2.
The Bland-Altman plot used for the evaluation of 
agreement between the Dimension Vista® 1500 
and the Beckman AU400® (Figure 1A) showed a 
mean difference of - 0.9 U/L (95% CI: - 1.82 to 0.02), 
lower limit of  - 6.5 U/L (95% CI: - 8.10 to - 4.94), up-
per limit of 4.7 U/L (95% CI: 3.14 to 6.30). Results of 
Passing-Bablok regression analysis are also shown 
(Figure 1B) (Slope = 1.02, 95% CI: 1.01 to 1.03; Inter-
cept = - 1.86, 95% CI: - 3.08 to - 1.26; R2 = 0.999).
No “hook effect” was observed for measured ab-
sorbance up to 450 OD x 103/min, corresponding 
to a nominal recombinant Lp-PLA2 activity of 1000 
U/L (Figure 2). Recovery was within 90 - 110%.
Albumin, bilirubin, haemoglobin, and triglycerides 
(20% Intralipid®) were tested as potentially inter-
fering endogenous substances as described in the 
Methods section. No interference was observed 
for haemoglobin up to 1.5 g/L, bilirubin up to 342 
Table 1. Precision evaluation of the lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyzer
Intra-assay imprecision Inter-assay imprecision
Study sample Lp-PLA2, U/L %CV
Package 
insert %CV Lp-PLA2, U/L %CV
Package 
insert %CV
Low Control 121 (1.5) 1.2 - 121 (2.4) 2.0 -
High Control 295 (2.5) 0.8 - 301 (4.1) 1.4 -
Serum #1 98 (0.6) 0.6 - 99 (0.9) 0.9 -
Serum #2 200 (2.9) 1.4 - 201 (2.8) 1.4 -
Serum #3 254 (2.4) 0.9 - 258 (3.0) 1.2 -
Range 98 – 295 (0.6 - 2.9) 0.6 - 1.4 1.3 - 1.4 99 – 301 (0.9 – 4.1) 0.9 - 2.0 1.9 - 2.6
Lp-PLA2 - lipoprotein-associated phospholipase A2. Lp-PLA2 activities are presented as mean (standard deviation). CV – coefficient 
of variation. For intra-assay imprecision evaluation, 20 replicates of each sample were measured in a single assay run. For inter-assay 
imprecision evaluation, 4 replicates of each sample were measured on 5 different days. Ranges of intra- and inter-assay %CVs 
obtained by the manufacturer on a Beckman Coulter AU400 analyzer (package insert) are also shown.
Table 2. Linearity evaluation of the lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyzer






#1 299 96 1.01 - 1.13 0.999 Slope: 0.98 - 1.03
#2 316 97 1.01 - 0.17 0.999 Intercept: - 6.8 - 10.7
#3 328 97 1.01 3.10 0.998 R2: 0.995 - 0.999
Three pairs of serum samples with high and low Lp-PLA2 activities were used to obtain 11 Lp-PLA2 activity levels in a serial 
recovery assay. Lp-PLA2 activity was measured in duplicate in each level and mean values were compared to expected activity 
values. Linearity results obtained by the manufacturer on a Beckman Coulter AU400 analyzer (package insert) are also shown.
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μmol/L, albumin up to 90 g/L (50 g/L spike + 40 
g/L in serum), and triglycerides up to 2.8 mmol/L.
Dose-response data for the determination of the 
in vitro IC50 of Darapladib were obtained by high 
precision Lp-PLA2 activity inhibition assay (0.50 to 
500 nM Darapladib spiked into multiple serum ali-
quots, baseline Lp-PLA2 activity range: 97 – 243 
U/L). These data were used to fit a dose-response 
curve to determine the IC50 of the drug. Calculat-
ed in vitro IC50 of Darapladib was < 50 nM.
Open vial reagents stability on-board the Dimen-
sion Vista® was demonstrated for 28 days by mean 
% difference from initial values of 2.1% (range: − 
0.5% to 3.8%) and 0.4% (range: - 3.1% to 2.7%) for 
low and high activity controls, respectively.
Table 3 shows the main biochemical characteris-
tics of 250 Italian adult healthy volunteers. In this 
population, Lp-PLA2 activity levels presented a 
Gaussian distribution (P = 0.98) ranging from 71 to 
290 U/L, with an average activity of 182 ± 44 U/L 
Figure 1. Comparison of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity values (N = 40) obtained on VISTA and AU400. 
(A) In the Bland-Altman plot the solid line shows mean difference, while the dashed lines show the ± 1.96 SD. (B) In the Passing-
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Figure 2. Hook effect evaluation of the lipoprotein-associated 
phospholipase A2 activity assay on the Dimension Vista analy-
ser. Substrate depletion hooks back measured ODs only at re-
combinant lipoprotein-associated phospholipase A2 (Lp-PLA2) 
activities > 1000 U/L.
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Table 3. Main clinical and laboratory characteristics of the study 
cohort of healthy donors
Males, N 123
Females, N 127
Age, years 37 (18 - 70)
Glucose, mmol/L 4.7 ± 0.5
Triglycerides, mmol/L 0.9 ± 0.3
Total cholesterol, mmol/L 4.3 ± 0.6
LDL, mmol/L 2.8 ± 0.5
HDL, mmol/L 1.4 ± 0.3
Age is presented as median (min-max). Results are presented 
as mean ± SD.
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(mean ± SD). When separate statistical analysis 
was performed by gender, a Gaussian distribution 
was also observed for each gender (males, P = 
0.90; females, P = 0.44). Mean Lp-PLA2 activity lev-
els in males were significantly higher than in fe-
males (203 ± 40 vs. 161 ± 37 U/L, respectively; P < 
0.001). Lp-PLA2 activity distribution amongst pop-
ulation percentiles and reference intervals are 
summarized in Table 4. In our population, no sta-
tistically significant correlation was found be-
tween Lp-PLA2 activity and LDL-cholesterol (di-
rectly measured), HDL-cholesterol, and triglycer-
ides. A moderate positive association was ob-
served between serum Lp-PLA2 activity and total 
cholesterol (r = 0.29, P < 0.001). No statistically sig-
nificant correlation between Lp-PLA2 activity and 
age.
Discussion
In consideration of the role of Lp-PLA2 as a poten-
tial marker of vascular inflammation in atheroscle-
rosis, we evaluated the analytical performance of 
the PLAC® Test for the measurement of Lp-PLA2 ac-
tivity on the Siemens Dimension Vista® 1500 plat-
form, for a possible application in routine clinical 
chemistry. Performance and practicability of the 
Dimension Vista® 1500 system are highly suitable 
for both routine and emergency use high-
throughput system. Correlation studies were per-
formed comparing our results obtained using the 
PLAC® Test for Lp-PLA2 Activity Kit on a Siemens 
Dimension Vista® 1500 instrument to values previ-
ously established by the manufacturer using a 
Beckman Coulter AU400® platform. We show that 
the PLAC® Test exhibits very good overall analyti-
cal performance characteristics on the Dimension 
Vista® 1500, as revealed by the results obtained for 
intra- and inter-assay precision, accuracy, linearity 
and sensitivity. Our results are comparable to the 
performance characteristics stated in the package 
insert of the PLAC® Test for Lp-PLA2 Activity Kit and 
to the assay performance established on other 
platforms and recently published by two inde-
pendent groups (18,19).
Substrate depletion experiments demonstrated 
that the PLAC® Test can be used on a Dimension 
Vista® analyzer to measure without analytical er-
rors Lp-PLA2 activities as high as 1000 U/L. This 
particular feature would allow the accurate evalua-
tion of patients at high and very high cardiovascu-
lar risk, whose Lp-PLA2 activities could be more el-
evated. Analytical interference that may common-
ly be exerted by high concentrations of some en-
dogenous substances (i.e., albumin, haemoglobin, 
and lipids) was also evaluated and turned out to 
be very moderate. Moreover, the Dimension Vista® 
analyzer specifically alerted for potential interfer-
ence according to standard HIL (haemolysis, icter-
us, and lipemia) indices. Open-vial stability of the 
PLAC Test® for Lp-PLA2 Activity reagents stored 
on-board the Dimension Vista® was evaluated by 
means of repeated measurements of Lp-PLA2 ac-
tivity using the same reagent set, controls, and cal-
ibration curve. Reagents were stable for up to 4 
weeks in the refrigerated compartment (2 - 8 °C) of 
the instrument, which is comparable to the stabili-
ty claims reported by the manufacturer for the 
PLAC Test® for Lp-PLA2 activity on other automat-
ed analytical systems. The maximum number of 
Table 4. Lipoprotein-associated phospholipase A2 activity val-









Minimum 71 87 71
2 .5 93 107 84
5 106 135 97
20 144 171 128
33 164 187 145
50 183 205 165
67 203 224 179
80 220 241 192
95 254 260 217
97 .5 262 265 225
Maximum 290 290 262
Mean 182 203 161
SD 44 40 37
2 .5-97 .5 93-262 107-265 84-225
Lp-PLA2 - lipoprotein-associated phospholipase A2.
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determinations performed with a single reagent 
cartridge (104 tests) is consistent with many other 
routine tests already validated for this analyzer.
Recently, Lp-PLA2 has been considered as a possi-
ble target for the treatment of atherosclerosis, and 
the selective Lp-PLA2 inhibitor Darapladib has 
been tested as a possible strategy for the preven-
tion and treatment of cardiovascular disease (24). 
However, the clinical trials conducted so far only 
yielded unsatisfactory results, so there is no evi-
dence yet to support a strategy of targeted Lp-
PLA2 inhibition (25,26). We used Darapladib to 
evaluate inhibitor effect on Lp-PLA2 activity in our 
samples. In agreement with previous findings, our 
selective inhibition results confirmed that the 
PLAC® Test allows the specific measurement of Lp-
PLA2 activity (24).
In the present work we also showed the results of 
preliminary population studies performed on a 
cohort of 250 Italian apparently healthy volunteers 
(123 males, 127 females, aged 18–70 years). We 
found that Lp-PLA2 activities presented a Gaussian 
distribution in the whole population as well as in 
the two gender groups, with mean Lp-PLA2 activi-
ty in males significantly higher than in females (P < 
0.001) which is in agreement with previously pub-
lished studies (27,28). Moreover, this study estab-
lishes for the first time RIs of serum LP-PLA2 activi-
ty in a healthy Italian population and proposes 
gender-specific RIs (107 - 265 U/L for males and 84 
- 225 U/L for females) for clinical practice.
Recent recommendations have been issued for 
Lp-PLA2 activity measurement especially in inter-
mediate cardiovascular risk patients, in order to 
decide whether they should be moved to a higher 
risk category (16,17). However, uniform reporting 
of clinically relevant cut-points for Lp-PLA2 activity 
in terms of increased risk for cardiovascular events 
has not been achieved yet. As claimed by the man-
ufacturer, the PLAC® Test incorporates a cut point 
of 225 U/L for Lp-PLA2 activity (which is expressed 
as nmol/min/mL in the package insert), which 
would identify patients at increased risk for coro-
nary heart disease (CHD) events. This value was 
derived from the results obtained by the analysis 
of plasma samples from 5446 subjects in the pla-
cebo arm of the JUPITER Study, by which a cut 
point of 225 U/L was derived to differentiate sub-
jects at increased risk for CVD events by Cox pro-
portional hazards regression (29). Use of the pro-
posed cut-point in our whole study population 
identifies 84% and 16% of the 250 subjects with 
low or high activity, respectively. In a population 
outcome-based sub-study conducted on nearly 
5000 subjects from the REGARDS Study, it has 
been shown that Lp-PLA2 activity above the sex-
specific 80th percentile (250 U/L in males, 200 U/L 
in females) was associated with CHD risk over 5.3 
years by Cox proportional hazards regression (30). 
These values are very similar to the sex-specific 
80th percentiles of our study population (241 U/L 
in males, 192 U/L in females). 
In the  healthy donor study cohort, there was no 
statistically significant association between age 
and Lp-PLA2 activity, while a moderate positive 
correlation was observed with Lp-PLA2 activity 
and total cholesterol, but not LDL cholesterol. This 
may well be due to the fact that part of Lp-PLA2 is 
carried by HDL also, while total cholesterol, which 
reflects the sum of LDL, HDL and, to a lower ex-
tent, other cholesterol carrying lipoproteins, is 
more directly associated with circulating Lp-PLA2. 
Although our research has reached its aims, this 
study has some limitations. In particular, the se-
lected population of healthy donors is relatively 
young (median age 37 years), and therefore our 
findings may not translate to older populations. 
Nevertheless, our preliminary data are encourag-
ing, and we are planning to extend this study in 
the future by increasing the number and age of 
enrolled participants. We also believe that further 
analysis of potential endogenous interferents (for 
example, higher concentrations of triglycerides) as 
well as selected exogenous agents such as lipid 
lowering drugs, would be valuable in order to 
meet suitable analytical conditions for the meas-
urement of Lp-PLA2 activity in patients with treat-
ed and untreated dyslipidemia.
Based on our results, we can conclude that the 
PLAC® Test allows accurate and precise measure-
ment of serum Lp-PLA2 activity on the Dimension 
Vista® 1500 automatic analyzer. Our findings add 
to the results previously obtained on other auto-
matic clinical chemistry analyzers, and can con-
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tribute to the method harmonization process for 
Lp-PLA2 activity measurement (18,19). Taken to-
gether, the high-throughput potential of the Di-
mension Vista® 1500 analyzer and the overall per-
formance characteristics of the PLAC® Test could 
provide a valuable tool for cardiovascular risk as-
sessment in both primary and secondary preven-
tion of cardiovascular disease, as well as for epide-
miological investigations.
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